English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe first trial presented – NRG Oncology NRG-GYO18 (NCT03914612) – was led by Ramez N. Eskander, MD, of the University of California San Diego, while the second trial presented – ENGOT-EN6-NSGO/GOG-3031/RUBY (NCT03981796), was led by Mansoor Mirza, MD, of the Finsen Center. Both were phase three, randomized, blinded studies.
In the GY-018 trial, 816 patients with stage III/IVA, IVB, or recurrent EC were randomized one-to-one to receive either immunotherapy pembrolizumab plus chemotherapy or placebo plus chemotherapy across six cycles, followed by up to 14 cycles of maintenance pembrolizumab or placebo. Of significance, patients in the mismatch repair-proficient EC cohort who received immunotherapy and chemotherapy experienced PFS for 11.7 months vs. 8.7 months among those receiving chemotherapy alone, with managed adverse effects.
In the RUBY trial, eligible patients (494) had first recurrent or primary advanced stage III or IV EC, and were randomized one-to-one to receive either immunotherapy dostarlimab plus chemotherapy, then monotherapy or placebo plus chemotherapy, then monotherapy. Among patients (245) who received both immunotherapy and chemotherapy, there was statistically significant and clinically meaningful progression free survival benefits across all populations compared with patients (249) treated with chemotherapy alone. An early trend toward improved overall survival was observed in all populations as well.
“Patients with advanced stage or recurrent endometrial cancer, the most common type of gynecologic cancer in the U.S., face a poor prognosis with limited treatment options,” said Eskander. “This is particularly notable in patients who progress after platinum-based adjuvant therapy with disease not amenable to curative surgery or radiation. In the GY-018 study, we saw clinically meaningful improvement in PFS in both study populations – an encouraging new finding. Future analysis will examine overall survival and quality of life outcomes.”
About SGO The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, SGO contributes to the advancement of gyn cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations. Learn more at www.sgo.org.
